The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
A new drug that targets a gene behind pancreatic cancer has physicians and researchers cautiously optimistic about improved treatment for one of the deadliest cancers.
Revolution Medicines, the pharmaceutical company behind the new drug, will release... [6955 chars]